modelPirenzepine
Extends from Pharmacolibrary.Drugs.ATC.A.A02BX03.
Information
| name: | Pirenzepine | |
| ATC code: | A02BX03 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 110 | ml/min |
| other parameters in model implementation | ||
Pirenzepine is a selective muscarinic M1 receptor antagonist used primarily in the past for the treatment of peptic ulcer disease and other gastric acid-related disorders. It reduces gastric acid secretion. It has largely fallen out of use and is no longer widely approved for current clinical use in many countries.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers after a single oral dose.
References
Bozler, G, & Hammer, R (1980). An international pharmacokinetic study on pirenzepine following a single oral dose. Scandinavian journal of gastroenterology. Supplement 66 27–33. PUBMED:https://pubmed.ncbi.nlm.nih.gov/6941374
Sathirakul, K, et al., & Wise, SD (2003). Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. British journal of clinical pharmacology 56(2) 184–187. DOI:10.1046/j.1365-2125.2003.01857.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12895191
Lane, HY, et al., & Chang, WH (2000). Disposition of olanzapine in Chinese schizophrenic patients. International journal of clinical pharmacology and therapeutics 38(10) 482–485. DOI:10.5414/cpp38482 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11073289
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)